Updated on 10 March 2014
In terms of disability, close to two-thirds had a ‘clinically important' reduction in disability and 45 per cent of patients who had been on disability leave at the outset of the study resumed work three months later.
Mainstay chief executive, Mr Peter Crosby said, "The results are, for us at least, pretty exciting. They show that the therapy that's delivered by our product appears to work and the results have certainly captured the attention of the clinical community with which we work."
The company said that it is hoping to be in a position to begin marketing Reactiv8 in Europe at the end of next year following the outcome of the trials in Australia.